{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:59:13Z","timestamp":1760061553818,"version":"3.37.3"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Substance P is readily expressed in skin inflammatory disorders such as psoriasis and contact dermatitis. Spantide II is a peptide (MW 1668.76) that specifically binds to neurokinin-1 receptor (NKR-1) and blocks inflammation associated with substance P. The anti-inflammatory property of Spantide II makes it a suitable candidate to be studied as a topical formulation for the treatment of dermal inflammatory disorders. The objective of this study was to investigate the influence of pH, temperature, salt concentration and concentration on the aqueous stability of Spantide II. The stability of Spantide II was also assessed by circular dichroic (CD) spectroscopy and mass spectrometry (MS). The influence of various dermatological vehicles (ethanol, Transcutol, propylene glycol, N-methyl-2-pyrrolidone (NMP), ethyl oleate, isopropyl myristate and laurogylcol FCC (LFCC)) on the stability of Spantide II was investigated. A precise high-performance liquid chromatography (HPLC) assay was developed for analysis of Spantide II. At higher temperature (40\u00b0C) the stability of Spantide II decreased with increase in pH (P &amp;lt; 0.05). Change in salt concentration did not appreciably affect the stability of Spantide II (P &amp;gt; 0.05). The concentration of Spantide II in the solution had no significant influence on its stability (P &amp;gt; 0.05). CD spectroscopy studies showed that Spantide II has a relatively stable \u03b1-helix structure in the liquid state. The stability of Spantide II was affected by the type of vehicle used in the study (P &amp;lt; 0.01) at different temperatures (P &amp;lt; 0.05). Spantide II at high temperature undergoes lysine\u2013proline diketopiperazine degradation as evident in MS data. Spantide II was relatively more stable in ethyl oleate\u2013ethanol, ethanol\u2013water, ethanol and N-methyl-2-pyrrolidone. The results of this study indicate that ethyl oleate\u2013ethanol (1:1) and ethanol\u2013water (1:1) could be used as potential vehicles in the development of topical formulations of Spantide II.<\/jats:p>","DOI":"10.1111\/j.2042-7158.2004.tb02573.x","type":"journal-article","created":{"date-parts":[[2010,2,26]],"date-time":"2010-02-26T16:24:57Z","timestamp":1267201497000},"page":"19-25","source":"Crossref","is-referenced-by-count":15,"title":["Preformulation stability of Spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis"],"prefix":"10.1093","volume":"56","author":[{"given":"Loice","family":"Kikwai","sequence":"first","affiliation":[{"name":"Division of Pharmaceutics, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University , Tallahassee, Florida,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R J","family":"Babu","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University , Tallahassee, Florida,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narayanasamy","family":"Kanikkannan","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University , Tallahassee, Florida,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandip","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutics, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University , Tallahassee, Florida,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2004,1,1]]},"reference":[{"key":"2024103109401750400_cit1","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0022-3565(24)37703-1","article-title":"Substance P induction of itch-associated response mediated by cutaneous NK1 tachykinin receptors in mice","volume":"286","author":"Andoh","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024103109401750400_cit2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/1523-1747.ep12330326","article-title":"Skin-nervous system interactions","volume":"106","author":"Ansel","year":"1996","journal-title":"J. Invest. Dermatol."},{"key":"2024103109401750400_cit3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/jidsymp.1997.6","article-title":"Interactions of the skin and nervous system","volume":"2","author":"Ansel","year":"1997","journal-title":"J. Invest. Dermatol. Symp. Proc."},{"key":"2024103109401750400_cit4","first-page":"229","article-title":"Sensory neuropeptides in the skin","volume-title":"Neurogenic inflammation","author":"Brain","year":"1996"},{"key":"2024103109401750400_cit5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1015835017916","article-title":"Chemical stability of insulin 1. Hydrolytic degradation during storage of pharmaceutical preparation","volume":"9","author":"Brange","year":"1992","journal-title":"Pharm. Res."},{"key":"2024103109401750400_cit6","first-page":"451","article-title":"Neuropeptide modulation of keratinocyte cytokine production","volume-title":"Molecular and cellular biology of cytokines","author":"Brown","year":"1990"},{"key":"2024103109401750400_cit7","first-page":"5","article-title":"Chemical and physical considerations in protein and peptide stability","volume-title":"Protein formulation and delivery","author":"Bummer","year":"2000"},{"key":"2024103109401750400_cit8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/archderm.1963.01590160042007","article-title":"Atrophic striae in patients with inguinal intertrigo","volume":"87","author":"Epstein","year":"1963","journal-title":"Arch. Dermatol."},{"key":"2024103109401750400_cit9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1021\/js970325m","article-title":"Kinetics of diketopiperazine formation using model peptides","volume":"87","author":"Goolcharran","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"2024103109401750400_cit10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0378-5173(91)90160-P","article-title":"Stability of the synthetic pentapeptide thymopentin in aqueous solution: effect of pH and buffer on degradation","volume":"70","author":"Helm","year":"1991","journal-title":"Int. J. Pharm."},{"key":"2024103109401750400_cit11","first-page":"350","article-title":"The ultraviolet circular dichroism of polypeptides","volume":"178","author":"Holzwarth","year":"1965","journal-title":"J. Am. Chem. Soc."},{"key":"2024103109401750400_cit12","first-page":"655","article-title":"Inhibition of allergic contact dermatitis by a topically applied SP receptor antagonist","volume":"119","author":"Jaiani","year":"2002","journal-title":"J. Invest. Dermatol."},{"key":"2024103109401750400_cit13","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1006\/jmbi.1997.0930","article-title":"Salt effects on protein stability: two-stranded alpha helical coiled-coils containing inter- or intrahelical ion pairs","volume":"267","author":"Kohn","year":"1997","journal-title":"J. Mol. Biol."},{"key":"2024103109401750400_cit14","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1023\/A:1015839719618","article-title":"Degradation of synthetic salmon calcitonin in aqueous solution","volume":"9","author":"Lee","year":"1992","journal-title":"Pharm. Res."},{"key":"2024103109401750400_cit15","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1023\/A:1015929109894","article-title":"Stability of protein pharmaceuticals","volume":"6","author":"Manning","year":"1989","journal-title":"Pharmacol. Res."},{"key":"2024103109401750400_cit16","first-page":"401","article-title":"Anti-inflammatory drugs","volume-title":"Lippincotts illustrated reveiws: pharmacology","author":"Mycek","year":"1992","edition":"2nd"},{"key":"2024103109401750400_cit17","first-page":"494","volume-title":"Anti-inflammatory steroid action","author":"Robertson","year":"1989"},{"key":"2024103109401750400_cit18","first-page":"41","article-title":"Stabilized soluble enzymes","volume":"12","author":"Schimid","year":"1970","journal-title":"Adv. Biochem. Eng."},{"key":"2024103109401750400_cit19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0625.1998.tb00307.x","article-title":"Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems","volume":"7","author":"Scholzen","year":"1998","journal-title":"Exp. Dermatol."},{"issue":"Suppl. 5","key":"2024103109401750400_cit20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-198800365-00005","article-title":"Side effects of topical corticoids and their prevention","volume":"36","author":"Takeda","year":"1988","journal-title":"Drugs"},{"key":"2024103109401750400_cit21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0378-5173(99)00152-0","article-title":"Instability, stabilization and formulation of liquid protein pharmaceuticals","volume":"185","author":"Wang","year":"1999","journal-title":"Int. J. Pharm."},{"key":"2024103109401750400_cit22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0014-2999(94)90327-1","article-title":"Pharmacological assessment of Spantide II analogues","volume":"260","author":"Wang","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"2024103109401750400_cit23","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0306-4522(91)90041-L","article-title":"Spantide II, a novel tachykinin antagonist, and galanin inhibit plasma extravasation induced by antidromic C-fiber stimulation in rat hindpaw","volume":"42","author":"Xu","year":"1991","journal-title":"Neuroscience"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.2042-7158.2004.tb02573.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/56\/1\/19\/60260504\/j.2042-7158.2004.tb02573.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/56\/1\/19\/60260504\/j.2042-7158.2004.tb02573.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T22:12:46Z","timestamp":1739916766000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/56\/1\/19\/6147229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2004,1,1]]},"published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.2042-7158.2004.tb02573.x","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"type":"print","value":"0022-3573"},{"type":"electronic","value":"2042-7158"}],"subject":[],"published-other":{"date-parts":[[2004,1]]},"published":{"date-parts":[[2004,1,1]]}}}